UMGCC Named One of "100 Hospitals and Health Systems With Great Oncology Programs"

For immediate release: March 20, 2013

The University of Maryland Marlene and Stewart Greenebaum Cancer Center has been named among “100 Hospitals With Great Oncology Programs” in the March 2013, issue of Becker's Hospital Review, a business and legal issues publication for health care leaders.

The list includes cancer programs that have been recognized for excellence in cancer care by third-party rating sources, such as U.S. News & World Report, the National Cancer Institute, the American College of Surgeons, the American Nurses Credentialing Center, and others.

Each program listed has, according to Becker’s, “demonstrated a focus on patient-centered care and emphasis on continual innovation in treatments and services. ...and many also have a place in the history of cancer prevention and research, as they’ve driven groundbreaking discoveries and made clinical milestones.”

UMGCC’s Advances in Cancer Research

UMGCC’s strong translational research program has made it a leader in cancer research discoveries. Examples of the scientific advances made by experts at the Greenebaum Cancer Center include:

  • Dr. Stuart Martin’s discovery that “microtentacles” on breast cancer cells play a key role in how cancers spread in the body.
  • Dr. Angela Brodie’s development of aromatase inhibitors for the treatment of breast cancer. Recent trials also showed that these drugs can prevent two thirds of cancers in women at high risk for developing the disease. Dr. Brodie and her colleagues have developed a new androgen synthesis inhibitor that shows great promise in treating prostate cancer.
  • Dr. Kevin Cullen’s research demonstrating for the first time that racial survival disparities in head and neck cancer are largely explained by previously unknown differences between racial and ethnic groups in the rate of human papillomavirus (HPV) infection.
  • UMGCC researchers’ pioneering work in stem cell and HIV/AIDS–related cancer studies in partnership with the University of Maryland Center for Stem Cell Biology and Regenerative Medicine and the Institute of Human Virology.

In addition, the Maryland Proton Treatment Center, under construction in the University of Maryland BioPark, will be a next-generation research center and radiation treatment facility expected to treat 2,000 cancer patients per year when fully operational.

For information about programs, treatments and services offered at the University of Maryland Greenebaum Cancer Center, please call 1-800-888-8823.